• 1. Ester-directed orthogonal dual C–H activation and ortho aryl C–H alkenylation via distal weak coordination?
  Manickam Bakthadoss,Tadiparthi Thirupathi Reddy,Vishal Agarwal,Duddu S. Sharada Chem. Commun., 2022,58, 1406-1409
• 2. Evidence that the availability of an allylic hydrogen governs the regioselectivity of the Wacker oxidation
  Matthew J. Gaunt,Jinquan Yu,Jonathan B. Spencer Chem. Commun., 2001, 1844-1845
• 3. Evidence of rutile-to-anatase photo-induced electron transfer in mixed-phase TiO2 by solid-state NMR spectroscopy?
  Weili Dai,Guangjun Wu,Michael Hunger Chem. Commun., 2015,51, 13779-13782
• 4. Excellent mechanical performance and enhanced dielectric properties of OBC/SiO2 elastomeric nanocomposites: effect of dispersion of the SiO2 nanoparticles?
  Xing Zhao,Lu Bai,Rui-Ying Bao,Zheng-Ying Liu,Ming-Bo Yang,Wei Yang RSC Adv., 2017,7, 46297-46305
• 5. Distinct correlation between (CN2)x units and pores: a low-cost method for predesigned wide range control of micropore size of porous carbon?
  Xiaotong Feng,Lei Bian,Jie Ma,Lei Zhou,Xiayan Wang,Guangsheng Guo,Qiaosheng Pu Chem. Commun., 2019,55, 3963-3966

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azaspirodecane derivatives Azaspirodecane derivatives
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azaspirodecane derivatives

Professional Introduction to Tert-butyl 1-oxo-2,8-diazaspiro[4.5]decane-8-carboxylate (CAS No. 268550-48-7)

Tert-butyl 1-oxo-2,8-diazaspiro[4.5]decane-8-carboxylate, identified by its Chemical Abstracts Service (CAS) number 268550-48-7, is a sophisticated heterocyclic compound that has garnered significant attention in the field of pharmaceutical chemistry and medicinal research. This compound belongs to the spirocyclic family, characterized by its unique structural framework where two or more rings are interconnected at one or more common atoms. The presence of both oxygen and nitrogen atoms in its molecular structure imparts distinctive electronic and steric properties, making it a promising candidate for various biochemical applications.

The molecular structure of tert-butyl 1-oxo-2,8-diazaspiro[4.5]decane-8-carboxylate consists of a spirocyclic core composed of a decane ring system with spiro connections between the fourth and fifth carbon atoms, creating a rigid framework that influences its chemical reactivity and biological interactions. The inclusion of an oxo group (C=O) at the 1-position and carboxylate functionality at the 8-position enhances its potential as a pharmacophore, enabling interactions with biological targets such as enzymes and receptors. Additionally, the tert-butyl group at the carboxylate position provides steric hindrance, which can modulate binding affinity and selectivity in drug design.

Recent advancements in medicinal chemistry have highlighted the significance of spirocyclic compounds due to their ability to exhibit conformational rigidity and unique spatial arrangements of functional groups. This structural motif has been leveraged to develop novel therapeutic agents with improved pharmacokinetic profiles and reduced side effects. The tert-butyl 1-oxo-2,8-diazaspiro[4.5]decane-8-carboxylate molecule exemplifies this trend, as its design allows for fine-tuning of electronic properties through modifications at key positions, such as the oxo and carboxylate groups.

In the realm of drug discovery, heterocyclic compounds like tert-butyl 1-oxo-2,8-diazaspiro[4.5]decane-8-carboxylate are particularly valuable due to their diverse biological activities. Studies have demonstrated that spirocyclic heterocycles can serve as scaffolds for developing compounds with antimicrobial, anti-inflammatory, and anticancer properties. The nitrogen atoms in the spirocyclic system can form hydrogen bonds or coordinate with metal ions, facilitating interactions with biological targets. Furthermore, the presence of both oxygen and nitrogen atoms allows for multiple modes of binding, enhancing the compound's potential as a lead molecule in drug development.

The carboxylate moiety in tert-butyl 1-oxo-2,8-diazaspiro[4.5]decane-8-carboxylate is particularly noteworthy for its role in modulating solubility and bioavailability. Carboxylate groups are known to enhance water solubility, which is crucial for oral and injectable formulations. Additionally, this functional group can participate in salt formation, allowing for the creation of derivatives with improved pharmacokinetic properties. The tert-butyl group further contributes to these properties by providing steric bulk that can influence solubility and metabolic stability.

Current research in synthetic organic chemistry has focused on developing efficient methodologies for constructing complex spirocyclic frameworks like those found in tert-butyl 1-oxo-2,8-diazaspiro[4.5]decane-8-carboxylate. Transition-metal-catalyzed reactions have emerged as powerful tools for achieving regioselective functionalization of heterocyclic systems. For instance, palladium-catalyzed coupling reactions have been employed to construct the spirocyclic core efficiently while maintaining high yields and selectivity. These advances have enabled chemists to explore novel derivatives of this compound with tailored biological activities.

The pharmaceutical industry has shown increasing interest in spirocyclic compounds due to their unique structural features and potential therapeutic applications. Tert-butyl 1-oxo-2,8-diazaspiro[4.5]decane-8-carboxylate is being investigated as a precursor for developing drugs targeting neurological disorders, where rigid scaffolds can improve binding affinity to protein targets involved in neurodegeneration. Additionally, its structural motifs have been explored in the design of antiviral agents, leveraging its ability to interact with viral proteases and enzymes essential for viral replication.

In conclusion,tert-butyl 1-oxo-2,8-diazaspiro[4.5]decane-8-carboxylate (CAS No. 268550-48-7) represents a fascinating example of how structural complexity can be harnessed to develop novel therapeutic agents. Its unique spirocyclic framework combined with functional groups such as oxo and carboxylate makes it a versatile scaffold for drug discovery efforts aimed at addressing various diseases. As synthetic methodologies continue to evolve and our understanding of biological targets deepens,tert-butyl 1-oxo-2,8-diazaspiro[4.5]decane-8-carboxylate is poised to play a significant role in the development of next-generation pharmaceuticals.

• 757949-27-2(1-Piperidinecarboxylic acid, 4-[(cyclohexylmethylamino)carbonyl]-,1,1-dimethylethyl ester)
• 916770-29-1(1-Piperidinecarboxylic acid, 4-[[(cyclohexylmethyl)amino]carbonyl]-,1,1-dimethylethyl ester)
• 254905-58-3(tert-Butyl 4-(dimethylcarbamoyl)piperidine-1-carboxylate)
• 544696-01-7(tert-Butyl 4-(methylcarbamoyl)piperidine-1-carboxylate)
• 752234-60-9(Tert-Butyl 1,3-Dioxo-2,8-Diazaspiro4.5Decane-8-Carboxylate)
• 874218-02-7(1-Piperidinecarboxylic acid,4-[[[[1-[(1,1-dimethylethoxy)carbonyl]-3-pyrrolidinyl]methyl]amino]carbonyl]-, 1,1-dimethylethyl ester)
• 757949-37-4(N-Butyl 1-BOC-piperidine-4-carboxamide)
• 1198284-94-4(tert-Butyl 1-oxo-2,9-diazaspiro[5.5]undecane-9-carboxylate)
• 188979-06-8(tert-Butyl 4-(Pyrrolidine-1-carbonyl)piperidine-1-carboxylate)
• 169206-67-1(Tert-butyl 3-oxo-2,8-diazaspiro[4.5]decane-8-carboxylate)